O
BMRN icon

Ossiam’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ossiam’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
21,829
+10,163
+87% +$593K 0.02% 204
2025
Q4 		$693K Sell
11,666
-5,791
-33% -$315K 0.01% 257
2025
Q3 		$945K Buy
17,457
+17,249
+8,293% +$986K 0.01% 484
2025
Q2 		$11.4K Hold
208
– – ﹤0.01% 624
2025
Q1 		$14.7K Sell
208
-268
-56% -$18K ﹤0.01% 599
2024
Q4 		$31.3K Sell
476
-2,369
-83% -$159K ﹤0.01% 590
2024
Q3 		$200K Sell
2,845
-121
-4% -$10.1K ﹤0.01% 538
2024
Q2 		$244K Buy
2,966
+5
+0.2% +$416 ﹤0.01% 524
2024
Q1 		$259K Sell
2,961
-1,704
-37% -$153K ﹤0.01% 555
2023
Q4 		$450K Buy
4,665
+1,946
+72% +$172K 0.01% 488
2023
Q3 		$241K Sell
2,719
-52
-2% -$4.63K ﹤0.01% 586
2023
Q2 		$240K Buy
2,771
+1,287
+87% +$121K ﹤0.01% 577
2023
Q1 		$144K Sell
1,484
-5,597
-79% -$580K ﹤0.01% 531
2022
Q4 		$733K Buy
7,081
+2,620
+59% +$246K 0.02% 314
2022
Q3 		$378K Sell
4,461
-1,302
-23% -$116K 0.01% 388
2022
Q2 		$478K Buy
5,763
+1,559
+37% +$124K 0.01% 317
2022
Q1 		$324K Buy
4,204
+1,866
+80% +$156K 0.01% 344
2021
Q4 		$207K Sell
2,338
-719
-24% -$59.3K 0.01% 365
2021
Q3 		$236K Hold
3,057
– – 0.01% 371
2021
Q2 		$235K Buy
3,057
+1,588
+108% +$126K 0.01% 371
2021
Q1 		$111K Buy
1,469
+726
+98% +$59.3K ﹤0.01% 381
2020
Q4 		$65K Buy
743
+624
+524% +$49.5K ﹤0.01% 376
2020
Q3 		$9K Sell
119
-2,016
-94% -$204K ﹤0.01% 385
2020
Q2 		$263K Sell
2,135
-9,493
-82% -$943K 0.02% 291
2020
Q1 		$983K Buy
11,628
+9,780
+529% +$843K 0.07% 176
2019
Q4 		$156K Buy
1,848
+1,626
+732% +$123K 0.01% 338
2019
Q3 		$15K Sell
222
-556
-71% -$42.8K ﹤0.01% 462
2019
Q2 		$67K Buy
+778
New +$66.6K 0.01% 399

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ossiam's BMRN Position: Q1 2026 in Review

Ossiam increased its BioMarin Pharmaceuticals (BMRN) stake by 87% in Q1 2026, buying an estimated $593K and bringing the position to 21,829 shares worth $1.23M. The position accounts for 0.02% of the portfolio, ranked #204.

Ossiam first reported a position in BMRN in Q2 2019 and has held it in 28 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Ossiam held 21,829 shares of BioMarin Pharmaceuticals worth $1.23M as of Q1 2026.
  • Ossiam bought 10,163 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $593K.
  • BioMarin Pharmaceuticals made up 0.02% of Ossiam's portfolio in Q1 2026, its #204 holding.
  • Ossiam first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.